Research Article
Improving the Lung Cancer Clinical Trial Development by Incorporating Competing Risk Factors
Table 2
Treatment-related adverse events (grade 3-5) and adverse events of respiratory (any grades).
| | Immunotherapy () | Chemotherapy () | Pembrolizumab () | Camrelizumab () | Atezolizumab () | Nivolumab () | |
| Grade 3-5 adverse event occurred | | | | | | White blood cell count decreased | 0 | 3 (13%) | 0 | 1 (5%) | 13 (29%) | Anemia | 0 | 3 (13%) | 1 (5%) | 0 | 1 (2%) | Platelet count decreased | 0 | 3 (13%) | 1 (5%) | 0 | | Neutropenia | 0 | 2 (8%) | 1 (5%) | 0 | 8 (18%) | Hyperglycemia | 0 | 1 (4%) | 0 | 0 | 0 | Leucoderma | 0 | 1 (4%) | 0 | 0 | 0 | Hemoptysis | 0 | 1 (4%) | 1 (5%) | 0 | 0 | Neutrophil count | 0 | 1 (4%) | 0 | 0 | 14 (31%) | Pneumonia | 0 | 1 (4%) | 0 | 0 | 0 | GGTP rise | 1 (8%) | 0 | 0 | 0 | 0 | Pancreatitis | 1 (8%) | 0 | 1 (5%) | 0 | 0 | Serum amylase increased | 0 | 0 | 1 (5%) | 0 | 0 | Erythra | 0 | 0 | 1 (5%) | 0 | 0 | Hyponatremia | 0 | 0 | 1 (5%) | 0 | 0 | Bone pain | 0 | 0 | 1 (5%) | 1 | 0 | Myelodysplastic syndrome | 0 | 0 | 1 (5%) | 0 | 0 | Lymphocyte count decreased | 0 | 0 | 0 | 1 | 3 (7%) | Fatigue | 0 | 0 | 0 | 1 | 1 (2%) | Leukopenia | 0 | 0 | 0 | 0 | 5 (11%) | Cough | 0 | 0 | 0 | 0 | 1 (2%) | Abducens nerve disorder | 0 | 0 | 0 | 0 | 2 (4%) | Intestinal obstruction | 0 | 0 | 0 | 0 | 1 (2%) | Zoster | 0 | 0 | 0 | 0 | 1 (2%) | Adverse events of respiratory (any grades) | | | | | | Pneumonia | 2(17%) | 2(9%) | 1(5%) | 2(11%) | 2(4%) | Cough | 10(83%) | 9(39%) | 11(58%) | 7(37%) | 23(51%) | Dyspnea | 0 | 11(4%) | 3(16%) | 1(5%) | 9(20%) | Fever | 0 | 0 | 2(11%) | 0 | 0 |
|
|